GENEVA, Switzerland, June 26, 2026
Johnson & Johnson presented 12 new scientific abstracts at the European Academy of Neurology (EAN) 2026 Congress, highlighting additional evidence supporting IMAAVY® (nipocalimab-aahu) in adults with antibody-positive generalized myasthenia gravis (gMG). New post-hoc analyses from the pivotal Phase 3 Vivacity-MG3 trial demonstrated that patients receiving IMAAVY plus standard of care experienced sustained disease control, including those diagnosed within five years, individuals with lower baseline symptom burden, and patients who developed common infections during treatment. The findings further reinforce the therapy’s ability to reduce pathogenic immunoglobulin G (IgG) autoantibodies through selective neonatal Fc receptor (FcRn) blockade, addressing one of the underlying drivers of gMG while preserving normal immune function.
Vivacity-MG3 Analyses Reinforce Sustained Clinical Benefits
The newly presented analyses showed that patients treated earlier in their disease course achieved greater improvements in Myasthenia Gravis Activities of Daily Living (MG-ADL) scores compared with placebo, while a higher proportion maintained meaningful clinical improvement for at least 20 weeks. Patients with milder disease at baseline also experienced significant reductions in symptom severity and improved daily functioning, suggesting that earlier intervention with IMAAVY may provide durable clinical benefits before disease progression becomes more advanced. Additional data demonstrated that patients maintained symptom control following common infections, which are known triggers for disease exacerbations in generalized myasthenia gravis. Safety findings remained consistent with previous studies, with no new safety signals identified and similar overall adverse event rates between the treatment and placebo groups.
PETUNIA Study Designed to Address Pregnancy Evidence Gap
Johnson & Johnson also introduced the design of the PETUNIA study, an innovative post-marketing research initiative that will collect real-world pregnancy, maternal, and infant outcomes following exposure to IMAAVY during pregnancy. The study combines prospective and retrospective data collection to generate evidence in an area where clinical information remains limited for women living with generalized myasthenia gravis. Researchers believe the project will provide valuable safety information to support physicians and patients when making treatment decisions during pregnancy while fulfilling an important FDA post-marketing commitment for the therapy.
Advertisement
IMAAVY Continues Expanding Its Role in Autoantibody Diseases
IMAAVY® (nipocalimab-aahu) is currently approved in both the United States and European Union for adults and adolescents aged 12 years and older with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody-positive generalized myasthenia gravis. Beyond gMG, Johnson & Johnson continues to investigate the FcRn-blocking therapy across a broad range of autoantibody-mediated diseases, including warm autoimmune hemolytic anemia, Sjögren’s disease, systemic lupus erythematosus, and several maternal-fetal disorders. The latest data presented at EAN 2026 further strengthen the growing clinical evidence supporting IMAAVY’s potential to provide long-term disease control, improve patient quality of life, and expand treatment options across multiple immune-mediated diseases.
Source: Johnson & Johnson press release
